Dana-Farber Cancer Institute | Strategic Alliance Partners

February 08, 2024

HPN328, was well tolerated and elicited responses in patients with neuroendocrine prostate cancer and other neuroendocrine neoplasms.

February 08, 2024

The expert panel explores belumosudil's role in treating chronic GVHD after multiple systemic therapy lines. They discuss the ROCKstar trial, highlighting its overall response rates and real-world experiences.

February 08, 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the approval and real-world experiences of ibrutinib and ruxolitinib for chronic GVHD. The panel discusses the challenges and varying effectiveness observed in real-world usage, contrasting the experiences of the two drugs.

February 06, 2024

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

February 06, 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

February 06, 2024

Drs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.

February 05, 2024

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

February 05, 2024

Sarah Sammons, MD, discusses the real-world incidence of brain metastases in HER2-positive breast cancer per line of treatment as well as cumulatively.

February 02, 2024

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.

February 02, 2024

Cancer survivors with elevated levels of NT-proBNP have a higher risk of death, according to an analysis conducted by Dana-Farber Cancer Institute.

February 02, 2024

The expert panel explores the approval of ruxolitinib for chronic GVHD based on the REACH3 trial. The panel highlights the trial’s outcomes, long-term follow-up data, and the evolving shift in clinical practices.

February 02, 2024

The panel examines the transition from systemic steroids to second-line therapies in chronic GVHD, explore standardized clinical trial definitions and real-world challenges in treating chronic GVHD.

January 30, 2024

Gabriela Hobbs, MD, discusses the significance of key research across myeloproliferative neoplasms from the 2023 ASH Annual Meeting.

January 30, 2024

Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.

January 30, 2024

Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.

January 30, 2024

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

January 30, 2024

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

January 27, 2024

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

January 26, 2024

Dana-Farber Cancer Institute researchers are the recipients of the Outstanding Investigator Award from the NCI, part of the National Institutes of Health.

January 25, 2024

Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.